Meta description: BridGene Biosciences has raised $28 million in Series B+ funding to drive clinical progress for oncology programs and expand its discovery platform.
BridGene Biosciences has completed a $28 million Series B+ funding round aimed at accelerating clinical trials for its lead cancer drug candidate and boosting development across its discovery pipeline. The announcement is relevant to startup founders, investors, and professionals tracking growth-stage biotech financing.
Who participated in the $28M funding round?
The Series B+ round was led by Bayland Capital, an investment firm focused on healthcare and life sciences. New investor GTJA Investment Group joined the round along with Proxima Ventures. Existing investors Lapam Capital and Grains Valley Venture Capital also contributed. This mix of strategic and venture capital investors reflects confidence in BridGene’s long-term potential.
The inclusion of both new investors and repeat backers suggests that prior performance and milestones have been met, creating trust in the company’s execution capability. For founders, this is a clear reminder of how maintaining relationships with existing capital providers can help secure future rounds.
How will the funding impact the clinical pipeline?
Proceeds are earmarked to advance BGC-515, a covalent TEAD inhibitor targeting solid tumors. The drug is currently in clinical development and planned to progress toward Phase 2 trials. The allocation of funds signals a push to achieve key proof-of-concept data.
The capital will also support the company’s second program, expected to enter clinical studies in 2027. These developments point to a staged approach where lead candidates move forward while pipeline diversification continues.
For business readers, this strategy spreads risk and maximizes the opportunity to capture value across multiple therapeutic areas.
What does this mean for BridGene’s discovery platform?
The company intends to expand its IMTAC chemoproteomic platform, which screens covalent small molecules in live cells to identify targets that are typically out of reach for conventional drug discovery methods. The funding will strengthen capabilities to explore oncology, autoimmune diseases, and neurology applications.
For investors, this platform expansion underpins future asset generation beyond the current pipeline. For startups in biotech, platform longevity and adaptability are important factors when pitching to investors.
Frequently Asked Questions
1. What stage is BGC-515 currently in?
It is in ongoing clinical development with plans to move into Phase 2 trials.
2. When will the second program start clinical trials?
The second program is targeted to enter the clinic in 2027.
3. Which sectors does the IMTAC platform address?
It has applications in oncology, immunology, autoimmune diseases, and neurology.
4. Why is investor diversity important for growth rounds?
Diverse backers bring different networks, expertise, and tolerance for risk, which strengthens overall strategic support.
Key takeaways
BridGene’s $28 million funding round brings together a mix of new and existing investors to drive forward oncology programs and expand discovery capabilities. The combination of platform investment and targeted drug program advancement positions the company for near-term clinical milestones and long-term asset creation.
Disclaimer
This content is for informational purposes only and should not be considered financial advice.